Keyphrases
Positron Emission Tomography
100%
Tumor Endothelial Cells
100%
Zirconium-89 (89Zr)
100%
Endosialin
100%
Ontuxizumab
100%
Sarcoma
27%
Antitumor
18%
Tumor
9%
Clinical Outcomes
9%
Immunoreactivity
9%
Clinical Trials
9%
Monoclonal Antibody
9%
Tumor Microenvironment
9%
Patient Selection
9%
Xenograft
9%
Patient Identification
9%
Biodistribution Studies
9%
Cell Surface Markers
9%
In Vivo Biodistribution
9%
Imaging Experiment
9%
Sarcoma Cells
9%
MORAb-004
9%
In Vivo Biomarkers
9%
Radiopharmaceutical Uptake
9%
Medicine and Dentistry
Positron Emission Tomography
100%
Zirconium 89
100%
Endosialin
100%
Ontuxizumab
100%
Connective Tissue Cancer
25%
Cell Line
16%
Biological Marker
8%
Neoplasm
8%
Clinical Trial
8%
Immunoreactivity
8%
Monoclonal Antibody
8%
Xenograft
8%
Tumor Microenvironment
8%
Patient Selection
8%
Biodistribution
8%
Cell Surface Marker
8%
Sarcoma Cell Line
8%
Radiopharmaceutical
8%